SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Xu Han – ‘SC 13D/A’ on 5/16/17 re: China Gewang Biotechnology, Inc.

On:  Tuesday, 5/16/17, at 9:26am ET   ·   Accession #:  1213900-17-5329   ·   File #:  5-88409

Previous ‘SC 13D’:  ‘SC 13D/A’ on 3/6/17   ·   Latest ‘SC 13D’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/16/17  Xu Han                            SC 13D/A               1:35K  China Gewang Biotechnology, Inc.  Edgar Agents LLC/FA

Amendment to General Statement of Beneficial Ownership   —   Sch. 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D/A    Amendment No. 2 to Schedule 13D                     HTML     20K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

  

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

SCHEDULE 13D/A

(Rule 13d-101)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULE 13d-1(a)

 

(Amendment No. 2)

  

CHINA GEWANG BIOTECHNOLOGY, INC.

(Name of Issuer)

 

Common Stock
(Title of Class of Securities)

  

16891W107
(CUSIP Number)

  

HAN XU

83 Taojin East Road, Room 401, Yuexiu District

Guangzhou City, Guangdong Province, P.R. China 510623

86-024-2397-4663

 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

May 15, 2017
(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(c), 13d-1(f) or 13d-1(g), check the following box.

 

 

 

 

 

 

CUSIP No. 16891W107 13D Page 2 of 4 Pages 

  

1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

 

Han Xu 

 

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 

(a) ☐

(b) ☐

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS *  

 

Not applicable

5.

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

 

 ☐

6.

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

P.R. China

NUMBER OF 7. SOLE VOTING POWER
SHARES   0
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY   0
EACH 9. SOLE DISPOSITIVE POWER
REPORTING   0
PERSON 10. SHARED DISPOSITIVE POWER
WITH   0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

0

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:

 

0%

14.

TYPE OF REPORTING PERSON

 

IN

  

 

 

 

Item 1. Security and Issuer

 

The class of equity securities to which this Schedule 13D relates is the Common Stock, $0.001 par value, (the “Common Stock”) of China Gewang Biotechnology, Inc., a Nevada corporation (the "Company"). The principal executive offices of the Company are located at Floor 29, No. 334, Huanshi East Road, Yuexiu District, Guangzhou City, Guangdong Province, P.R. China 510623.

 

Item 2. Identity and Background

 

a.Name:     Han Xu
b.Residence and Business Address:     No. 83 Taojin East Road, Yuexiu District, Guangzhou City, Guangdong Province, P.R. China 510623
c.Present employment: - Self
d.During the past five years, Han Xu has not been convicted in any criminal proceeding.
e.During the past five years, Han Xu has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which she was subject to any judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
f.Peoples Republic of China

 

Item 3. Source and Amount of Funds or Other Consideration.

 

The filing of the initial schedule was necessitated by a grant of voting rights to the Reporting Person. No funds or other consideration were exchanged. The filing of this amendment is necessitated by the termination of those voting rights.

 

Item 4. Purpose of Transaction.

 

At the time of her acquisition of beneficial interest in the Company’s shares, the Reporting Person has no plan or proposal which relates to or would result in any of the actions or transactions described in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D.

 

Item 5. Interest in Securities of the Issuer.

 

(a) The information regarding share ownership by the Reporting Person provided on her cover page is incorporated here by reference.

 

(b) The information regarding share ownership by the Reporting Person provided on her cover page is incorporated here by reference.

 

(c) The Reporting Person has not effected any transactions in the shares of the Company's equity securities within the past 60 days.

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships.

 

On January 18, 2016 Xiuqin Jiang and Jun Wen signed an Authorization that gave Han Xu voting power over shares owned by those two individuals personally. At the present time, Xiuqin Jiang owns 2,971,500 shares personally and Jun Wen owns 5,000,000 shares personally. On May 15, 2017 Xiuqin Jiang and Jun Wen terminated the Authorization.

 

On May 16, 2016 Hong Kong Quansheng Holding Management Co., Limited signed an Authorization that gave Han Xu voting power over 10,000,000 shares owned by that entity. On May 15, 2017 Hong Kong Quansheng Holding Management Co., Limited terminated the Authorization.

 

On May 16, 2016 Mengdi Zhang executed an Authorization assigning to Han Xu the voting rights with respect to 9,500,000 shares owned by Mengdi Zhang and 7,500,000 shares owned by Hong Kong Nuoxin Investment Management Co., Ltd. Mengdi Zhang has subsequently disposed of the 9,500,000 shares owned by her directly. On May 15, 2017 Mengdi Zhang terminated the Authorization.

 

Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person named in Item 2 hereof and any person with respect to any securities of the Company, including but not limited to transfer or voting of any other securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

 

Item 7. Material to be Filed as Exhibits.

 

Not applicable.

 

Page 3 of 4 Pages 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 16, 2017 /s/ Han Xu
  Han Xu

 

 

Page 4 of 4 Pages

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘SC 13D/A’ Filing    Date    Other Filings
Filed on:5/16/178-K,  SC 13D/A
5/15/178-K
5/16/163,  8-K
1/18/163,  8-K
 List all Filings 
Top
Filing Submission 0001213900-17-005329   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 4:08:50.1am ET